NCT03104179

Brief Summary

In a lot of cases during cardiac surgery cardiopulmonary bypass initiates SIRS due to release of cytokines during immunological response. They are induced by different types of inductors ( intrinsic and extrinsic). High levels of inflammation markers like TNF-a, IL 6 and IL 10 as well as TGF-ß are detectable after 2 hours of surgery. Beside the inflammation acute phase parameters like fibrinogen, ferritin are increased. These changes lead to rheology impairments. These strong reactions lead to dysfunction of different organs possibly culminating in a multi organ failure. There is a correlation between amounts of cytokines and mortality. Often AKI occurs after CPB with a rate of about 30%. Dysfunctions of organ function are often connected with increased mortality, prolonged mechanical ventilation , septic complications, increased catecholamine dosages and prolonged length of ICU stay. Use of cytokine adsorption within the extracorporeal circuit during CBP can affect the circulating cytokine levels during and after CPB and lead to a diminished inflammatory response, acute phase reaction as well as reduction of organ failure.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 16, 2015

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

April 7, 2017

Completed
24 days until next milestone

Study Start

First participant enrolled

May 1, 2017

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2019

Completed
Last Updated

April 7, 2017

Status Verified

March 1, 2017

Enrollment Period

2 years

First QC Date

June 16, 2015

Last Update Submit

March 31, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cytokine levels following CPB

    Evaluation of cytokine adsorber effect on cytokine levels intra- and post

    72 hours

Secondary Outcomes (7)

  • Intra- and postoperative catecholamine dosages

    until ICU discharge, expected average 4 days

  • postoperative renal failure necessitating RRT

    until ICU discharge, expected average 4 days

  • Level of ferritin

    72 hours

  • Level of transferrin

    72 hours

  • Level of haptoglobin

    72 hours

  • +2 more secondary outcomes

Other Outcomes (1)

  • Mortality

    28 days

Study Arms (2)

Treatment

EXPERIMENTAL

CPB with Cytosorb

Device: Cytosorb Adsorber

Control

NO INTERVENTION

CPB without Cytosorb (Control)

Interventions

Cytokine adsorption during CPB

Treatment

Eligibility Criteria

Age65 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Elective cardiac surgery with CPB
  • Signed informed consent
  • CPB time \> 75 min.
  • Comorbidities:
  • diabetes mellitus
  • CHF, NYHA class 1 and 2
  • liver dysfunction (1, 2)
  • kidney dysfunction (1, 2)
  • hypertension
  • arteriosclerosis

You may not qualify if:

  • Age \< 65 years
  • Declined informed consent
  • Planed temperature \< 32 C
  • Emergency surgery
  • Preexisting renal replacement therapy
  • Preexisting kidney transplantation
  • Administration of immunosuppressants like steroids
  • AIDS with CD 4 \< 200/
  • Participation in other trials

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Klinikum Nürnberg - Nuremberg Hospital

Nuremberg, Bavaria, 90471, Germany

Location

Related Publications (5)

  • Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003 Feb;75(2):S715-20. doi: 10.1016/s0003-4975(02)04701-x.

    PMID: 12607717BACKGROUND
  • Allan CK, Newburger JW, McGrath E, Elder J, Psoinos C, Laussen PC, del Nido PJ, Wypij D, McGowan FX Jr. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg. 2010 Nov;111(5):1244-51. doi: 10.1213/ANE.0b013e3181f333aa. Epub 2010 Sep 9.

    PMID: 20829561BACKGROUND
  • Bellomo R, Auriemma S, Fabbri A, D'Onofrio A, Katz N, McCullough PA, Ricci Z, Shaw A, Ronco C. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int J Artif Organs. 2008 Feb;31(2):166-78. doi: 10.1177/039139880803100210.

    PMID: 18311733BACKGROUND
  • Blomquist S, Gustafsson V, Manolopoulos T, Pierre L. Clinical experience with a novel endotoxin adsorbtion device in patients undergoing cardiac surgery. Perfusion. 2009 Jan;24(1):13-7. doi: 10.1177/0267659109106730.

    PMID: 19567543BACKGROUND
  • Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, Wen XY, Rimmele T, Singbartl K, Federspiel WJ, Clermont G, Kellum JA. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012 Feb;81(4):363-9. doi: 10.1038/ki.2011.320. Epub 2011 Sep 14.

    PMID: 21918497BACKGROUND

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PD, Dr. med

Study Record Dates

First Submitted

June 16, 2015

First Posted

April 7, 2017

Study Start

May 1, 2017

Primary Completion

May 1, 2019

Study Completion

May 1, 2019

Last Updated

April 7, 2017

Record last verified: 2017-03

Data Sharing

IPD Sharing
Will not share

Locations